ERBB2 and breast carcinoma: IBC currently lacks any targeted treatment strategies (apart from trastuzumab and pertuzumab for HER2-overexpressing tumors) and, due to its intrinsic aggressiveness, confers a poorer prognosis than other stage- and subtype-matched breast cancers.